LOGIN  |  REGISTER
Viking Therapeutics
Terns Pharmaceuticals

Spok to Present and Host 1x1 Investor Meetings at the 35th Annual Piper Sandler & Co. Healthcare Conference

November 16, 2023 | Last Trade: US$15.67 0.26 1.69

ALEXANDRIA, Va. / Nov 16, 2023 / Business Wire / Spok Holdings, Inc. (NASDAQ: SPOK), a global leader in healthcare communications, today announced that Vincent D. Kelly, chief executive officer, will participate in the 35th annual Piper Sandler & Co. healthcare conference on November 29, 2023 in New York. The Company’s presentation is scheduled for 12:30 pm ET. Spok will also host a series of 1X1 meetings with investors on November 29, 2023.

The presentation will also be webcast and can be accessed via the conference presentation link, and in the investor relations section of the Company's website: http://www.spok.com.

About Spok

Spok, Inc., a wholly owned subsidiary of Spok Holdings, Inc. (NASDAQ: SPOK), headquartered in Alexandria, Virginia, is proud to be a global leader in healthcare communications. We deliver clinical information to care teams when and where it matters most to improve patient outcomes. Top hospitals rely on the Spok Care Connect® platform to enhance workflows for clinicians and support administrative compliance. Our customers send over 70 million messages each month through their Spok® solutions. Spok enables smarter, faster clinical communication. For more information, visit spok.com.

Spok is a trademark of Spok Holdings, Inc. Spok Care Connect and Spok Mobile are trademarks of Spok, Inc.

Assertio

Stock Quote

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page